Karyopharm Initiates Second Generation SINE™ Compound Clinical Trial in Multiple Myeloma
January 19, 2016 07:00 ET
|
Karyopharm Therapeutics
NEWTON, Mass., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today the initiation of a Phase 1/2 study of oral...
Karyopharm Initiates Clinical Trial of Oral Selinexor in Advanced Liposarcoma
January 14, 2016 07:00 ET
|
Karyopharm Therapeutics
NEWTON, Mass., Jan. 14, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today the initiation of Selinexor in Advanced...
Karyopharm to Present at the 34th Annual J.P. Morgan Healthcare Conference
January 04, 2016 08:00 ET
|
Karyopharm Therapeutics
NEWTON, Mass., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief...
Karyopharm Therapeutics Presents Positive Clinical Data on the Activity of Selinexor in Combination with Other Anticancer Agents across Multiple Hematologic Malignancies at the 2015 American Society of Hematology (ASH) Annual Meeting
December 07, 2015 10:00 ET
|
Karyopharm Therapeutics
- Selinexor Demonstrates Promising Activity and Tolerability in Combination with Other Active Agents -
- Encouraging Efficacy and Tolerability Observed in Patients with Heavily Pretreated...
Karyopharm to Present Clinical Data Update for Selinexor (KPT-330) in Hematologic Malignancies
November 30, 2015 16:01 ET
|
Karyopharm Therapeutics
NEWTON, Mass., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the presentation of clinical data for its lead...
Karyopharm Reports Third Quarter 2015 Financial Results and Highlights Recent Progress
November 09, 2015 07:30 ET
|
Karyopharm Therapeutics
– Robust Recruitment and New Study Initiations Continue –
– Additional Encouraging Data on Selinexor in Combination with Other Active Agents to be Presented at ASH...
Karyopharm to Present Data on Oncology Pipeline at American Society of Hematology 2015 Annual Meeting
November 05, 2015 09:05 ET
|
Karyopharm Therapeutics
NEWTON, Mass., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that 17 abstracts, including 5 oral presentations...
Karyopharm to Report Third Quarter 2015 Financial Results on November 9, 2015
November 02, 2015 08:00 ET
|
Karyopharm Therapeutics
NEWTON, Mass., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report third quarter 2015 financial...
Karyopharm Initiates STOMP Clinical Trial of Oral Selinexor in Multiple Myeloma
October 19, 2015 08:00 ET
|
Karyopharm Therapeutics
NEWTON, Mass., Oct. 19, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today the initiation of the Selinexor and Backbone...
Karyopharm Advancing Neuroprotective SINE(TM) Compounds in Amyotrophic Lateral Sclerosis (ALS)
September 03, 2015 08:00 ET
|
Karyopharm Therapeutics
– Preclinical efficacy of SINE™ compounds validated in journal Nature publication –
– Presentations of ALS abstracts at upcoming AAN and SfN meetings –
–...